Is OMER or NKTR more profitable?

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Nektar Therapeutics -284.18% -85.40% -39.99%

Does the media refer more to OMER or NKTR?

In the previous week, Nektar Therapeutics had 8 more articles in the media than Omeros. MarketBeat recorded 15 mentions for Nektar Therapeutics and 7 mentions for Omeros. Omeros' average media sentiment score of 0.32 beat Nektar Therapeutics' score of 0.02 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media refer more to OMER or PRGO?

In the previous week, Perrigo had 7 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Perrigo and 7 mentions for Omeros. Omeros' average media sentiment score of 0.32 beat Perrigo's score of 0.01 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PCRX or OMER more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Pacira BioSciences 0.70% 10.24% 5.47% Omeros N/A -102.16% 64.87%

Does the media prefer PCRX or OMER?

In the previous week, Pacira BioSciences had 3 more articles in the media than Omeros. MarketBeat recorded 10 mentions for Pacira BioSciences and 7 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.58 beat Omeros' score of 0.32 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OMER or ASMB?

In the previous week, Omeros had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Omeros and 5 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.32 beat Assembly Biosciences' score of 0.31 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Omeros (OMER) Competitors

$10.16 -0.10 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$10.15 -0.01 (-0.10%)

As of 06:18 PM Eastern

Compare

OMER vs. SUPN, NKTR, PRGO, PCRX, and ASMB

Should you buy Omeros stock or one of its competitors? MarketBeat compares Omeros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omeros include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Omeros compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

In the previous week, Omeros had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 7 mentions for Omeros and 1 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.71 beat Omeros' score of 0.32 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Positive
Omeros	Neutral

48.8% of Omeros shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 12.9% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Omeros	N/A	-102.16%	64.87%

Omeros has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.55	-$38.55M	-$0.51	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.51

Supernus Pharmaceuticals presently has a consensus price target of $62.17, suggesting a potential upside of 41.19%. Omeros has a consensus price target of $40.33, suggesting a potential upside of 296.98%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Supernus Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Omeros has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market.

Summary

Omeros beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Omeros compare to Nektar Therapeutics?

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.51
Nektar Therapeutics	$55.63M	35.97	-$164.08M	-$8.42	N/A

In the previous week, Nektar Therapeutics had 8 more articles in the media than Omeros. MarketBeat recorded 15 mentions for Nektar Therapeutics and 7 mentions for Omeros. Omeros' average media sentiment score of 0.32 beat Nektar Therapeutics' score of 0.02 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Omeros presently has a consensus target price of $40.33, suggesting a potential upside of 296.98%. Nektar Therapeutics has a consensus target price of $149.63, suggesting a potential upside of 152.62%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Omeros beats Nektar Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Omeros compare to Perrigo?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

48.8% of Omeros shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 12.9% of Omeros shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Perrigo had 7 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Perrigo and 7 mentions for Omeros. Omeros' average media sentiment score of 0.32 beat Perrigo's score of 0.01 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

Omeros presently has a consensus target price of $40.33, indicating a potential upside of 296.98%. Perrigo has a consensus target price of $19.33, indicating a potential upside of 85.27%. Given Omeros' stronger consensus rating and higher probable upside, equities research analysts plainly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.51
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A

Summary

Omeros beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Omeros compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Omeros	N/A	-102.16%	64.87%

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 12.9% of Omeros shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.21	$7.03M	$0.12	186.00
Omeros	N/A	N/A	-$3.35M	$0.70	14.51

Pacira BioSciences has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

In the previous week, Pacira BioSciences had 3 more articles in the media than Omeros. MarketBeat recorded 10 mentions for Pacira BioSciences and 7 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.58 beat Omeros' score of 0.32 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacira BioSciences presently has a consensus price target of $29.40, indicating a potential upside of 31.72%. Omeros has a consensus price target of $40.33, indicating a potential upside of 296.98%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Pacira BioSciences beats Omeros on 9 of the 16 factors compared between the two stocks.

How does Omeros compare to Assembly Biosciences?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Omeros has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

In the previous week, Omeros had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Omeros and 5 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.32 beat Assembly Biosciences' score of 0.31 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros currently has a consensus target price of $40.33, indicating a potential upside of 296.98%. Assembly Biosciences has a consensus target price of $42.75, indicating a potential upside of 73.99%. Given Omeros' stronger consensus rating and higher probable upside, equities research analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.51
Assembly Biosciences	$71.10M	5.49	-$6.12M	-$0.11	N/A

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

48.8% of Omeros shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 12.9% of Omeros shares are held by insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Omeros beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$735.38M	$7.86B	$6.25B	$12.42B
Dividend Yield	N/A	2.56%	2.69%	5.29%
P/E Ratio	14.51	15.39	22.29	24.19
Price / Sales	N/A	5.69	581.44	138.36
Price / Cash	5.73	17.23	42.31	57.88
Price / Book	-5.94	3.53	9.84	6.72
Net Income	-$3.35M	$224.05M	$3.57B	$337.19M
7 Day Performance	-8.22%	-1.11%	-1.17%	0.48%
1 Month Performance	-32.54%	0.31%	3.84%	5.06%
1 Year Performance	223.57%	-0.30%	27.39%	34.27%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	3.12 of 5 stars	$10.16 -1.0%	$40.33 +297.0%	+233.1%	$735.38M	N/A	14.51	210
SUPN Supernus Pharmaceuticals	3.229 of 5 stars	$44.76 -3.1%	$62.17 +38.9%	+38.1%	$2.68B	$718.95M	N/A	580
NKTR Nektar Therapeutics	2.5904 of 5 stars	$63.86 -1.6%	$149.63 +134.3%	+390.2%	$2.19B	$55.23M	N/A	220	Analyst Revision
PRGO Perrigo	3.8065 of 5 stars	$10.75 -2.8%	$19.33 +79.9%	-60.9%	$1.53B	$4.18B	N/A	8,100
PCRX Pacira BioSciences	3.8825 of 5 stars	$22.96 -1.1%	$29.40 +28.0%	-15.2%	$913.66M	$734.86M	191.35	720

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. SUPN, NKTR, PRGO, PCRX, and ASMB

How does Omeros compare to Supernus Pharmaceuticals?

Summary

How does Omeros compare to Nektar Therapeutics?

Summary

How does Omeros compare to Perrigo?

Summary

How does Omeros compare to Pacira BioSciences?

Summary

How does Omeros compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. SUPN, NKTR, PRGO, PCRX, and ASMB

How does Omeros compare to Supernus Pharmaceuticals?

Does the media prefer SUPN or OMER?

Do insiders & institutionals hold more shares of SUPN or OMER?

Is SUPN or OMER more profitable?

Which has preferable earnings & valuation, SUPN or OMER?

Do analysts rate SUPN or OMER?

Which has more volatility and risk, SUPN or OMER?

Summary

How does Omeros compare to Nektar Therapeutics?

Which has higher earnings & valuation, OMER or NKTR?

Does the media refer more to OMER or NKTR?

Which has more volatility & risk, OMER or NKTR?

Is OMER or NKTR more profitable?

Do insiders and institutionals have more ownership in OMER or NKTR?

Do analysts rate OMER or NKTR?

Summary

How does Omeros compare to Perrigo?

Which has more risk & volatility, OMER or PRGO?

Do institutionals & insiders have more ownership in OMER or PRGO?

Does the media refer more to OMER or PRGO?

Is OMER or PRGO more profitable?

Do analysts recommend OMER or PRGO?

Which has higher valuation & earnings, OMER or PRGO?

Summary

How does Omeros compare to Pacira BioSciences?

Is PCRX or OMER more profitable?

Do institutionals and insiders believe in PCRX or OMER?

Which has better valuation and earnings, PCRX or OMER?

Which has more risk & volatility, PCRX or OMER?

Does the media prefer PCRX or OMER?

Do analysts rate PCRX or OMER?

Summary

How does Omeros compare to Assembly Biosciences?

Which has more risk and volatility, OMER or ASMB?

Does the media refer more to OMER or ASMB?

Do analysts prefer OMER or ASMB?

Which has stronger earnings & valuation, OMER or ASMB?

Is OMER or ASMB more profitable?

Do insiders and institutionals believe in OMER or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools